Cargando…
Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms
Class IB phosphoinositide 3-kinase gamma (PI3Kγ) is vital for regulating intracellular signaling pathways and has become an attractive drug target for the treatment of malignant tumors. In the present study, one potent PI3Kγ inhibitor (JN-PK1) with a novel scaffold against hematologic malignancies w...
Autores principales: | Zhu, Jingyu, Ke, Ke, Xu, Lei, Jin, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087882/ https://www.ncbi.nlm.nih.gov/pubmed/35546906 http://dx.doi.org/10.1039/c9ra02649e |
Ejemplares similares
-
The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
por: Faia, Kerrie, et al.
Publicado: (2018) -
Genetic enhancement of behavioral itch responses in mice lacking phosphoinositide 3-kinase-γ (PI3Kγ)
por: Lee, Bolam, et al.
Publicado: (2011) -
Roles of phosphatidyl inositol 3 kinase gamma (PI3Kγ) in respiratory diseases
por: Sala, Valentina, et al.
Publicado: (2021) -
QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using MLR and ANN methods
por: Sadeghi, Fereydoun, et al.
Publicado: (2022) -
Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)